

1 Supplement

2 eMethods

3 PET-based staging systems

4 PET-based staging systems were included as non-binary categorical measures
5 of A β and tau pathology. We included two systems for A β : a three-stage system
6 developed by Mattsson et al¹ and a four-stage system developed by Collij et al². We
7 included Braak staging for tau^{3,4}, including both a three-stage and six-stage version.
8 Each stage in each system was associated with a collection of Freesurfer ROIs (stage
9 composite), as shown in eTable 2, with advancing stages indicating regions where
10 pathology spreads over the disease course.

11 The method for Mattsson staging and Braak staging were similar and proceeded
12 as follows. First, an average SUVR was calculated in each stage composite using a
13 volume weighted average of bilateral regions. Next, Gaussian mixture models (GMM)
14 were fit to the distribution of uptake in each stage composite to estimate a binary cutoff
15 for stage positivity (as described in the main text Methods: Image-based biomarker
16 definitions). These cutoffs allowed us to assign binary positivity measures for each
17 subject in each stage composite. Disease stages were then assigned based on
18 individual patterns of positivity: to be assigned a given disease stage, an individual had
19 to exhibit positivity for that stage and all prior ones. In case an individual was positive
20 for a given stage but not all prior stages, they were marked as non-stageable.
21 Individuals could also be assigned stage 0 if they were not positive for pathology in any
22 stage composite.

23 Collij staging was slightly different in that positivity for a stage composite was
24 based on being positive for pathology in most ROIs corresponding to a given stage.
25 That is, GMMs were fit to each Freesurfer ROI individually, and positivity for a stage
26 composite was defined by exhibiting supra-threshold uptake in 50% or more of the

27 associated ROIs. Disease stage assignment then proceeded in the same manner as
28 for Mattsson and Braak staging (individuals needed to be positive for a given disease
29 stage and all prior stages).

30 Cross-validation experiments

31 Cross-validated modeling was implemented in Python (v3.10) using scikit-learn
32 (v1.4.2). For all cross-validation experiments, CDR status was used as a stratifying
33 variable. Random samples were also seeded, such that the individuals of each testing
34 fold were the same across experiments with the same input data. All cross-validation
35 experiments had 10 outer folds and were repeated 10 times to generate 100 out of
36 sample error estimates for each tested model.

37 We first ran models for each biomarker separately to assess the predictive value
38 of each included definition. These experiments used a non-nested, 10-fold cross-
39 validation. In each iteration, training data were used to fit linear regressions where
40 PHC_{Global} was predicted from a single biomarker and covariates (age, sex, *APOE* E4
41 positivity). That is, separate models were fit for each biomarker. Biomarker definitions
42 with tunable parameters (Z-scores, GMMs) were also fit with training data. A baseline
43 model was also trained in each iteration which only included covariates as predictors.
44 Trained models were then evaluated on the testing fold data, and the prediction
45 accuracies for each were calculated as root mean squared error (RMSE).

46 We next created combinatorial models to test if combination of biomarkers
47 improved prediction accuracy and if models incorporating continuous or non-categorical
48 binary biomarkers outperformed models with binary biomarkers. For these
49 experiments, we used nested cross-validation with 10 outer folds and 5 inner folds. In
50 the inner cross-validation, a model selection procedure was applied to identify the best
51 performing individual predictors (like the non-nested cross-validation experiment
52 described above). Inner training data were used to fit linear models predicting PHC_{Global}
53 with single biomarkers plus covariates as predictors. Inner testing data were used to
54 measure the out-of-sample accuracy of these models. We then grouped the models
55 based on the pathology (AT(N)) and variable type (binary/non-binary

56 categorical/continuous) and selected the best performing biomarker definitions (lowest
57 average RMSE across 5 test folds). The outer cross-validation was then used for
58 training new linear models which combined the biomarkers selected from the inner
59 cross-validation. eTable 3 shows all the combinatorial linear models that were
60 evaluated in the outer loop using this training scheme.

61 We also used support vector machine (SVM) regression to directly predict
62 $\text{PHC}_{\text{Global}}$ from imaging data. SVMs were trained using regional $A\beta$ uptakes, tau
63 uptakes, or gray matter volumes as input features. An additional model combined all
64 these regional imaging features into a multimodal predictive model. SVM training used
65 a nested cross-validation design with 10 outer folds and 5 inner folds. The inner loop
66 was used for hyperparameter tuning for the regularization parameter C , the kernel, and
67 the kernel coefficient γ . Search spaces were informed by consensus
68 recommendations⁵ and from pilot experiments: kernel (linear or radial basis function
69 [RBF]), C with linear kernel ($2^{-10}, 2^{-9}, \dots, 2^{-1}, 2^0$), C with RBF kernel
70 ($2^{-5}, 2^{-3}, \dots, 2^{13}, 2^{15}$), γ with RBF kernel ($2^{-15}, 2^{-13}, \dots, 2^1, 2^3$). The best
71 hyperparameters were determined from the inner loop (lowest average RMSE across 5
72 test folds) and used to retrain and evaluate SVM models in the outer loop.

73 Feature importance analyses

74 We ran additional post-hoc analyses to probe feature importance for our cross-
75 validated linear modeling. For models which applied a model selection to filter
76 biomarker definitions, we created pie charts showing the specific biomarker definitions
77 which were selected as the best performing over repeated cross-validation iterations.
78 We also extracted and plotted the (standardized) linear model coefficients for the $A\beta$,
79 tau, and neurodegeneration biomarkers in all binary and all continuous models (non-
80 binary categorical models were omitted because coefficient interpretation is less
81 straightforward for non-binary categorical features). Finally, we visualized the cutoff
82 values that were selected for $A\beta$ and tau from models with all binary definitions.

83 For SVM models, we visualized the feature importance of individual brain regions
84 for $A\beta$, tau, and neurodegeneration features. Following previous work^{6,7}, feature

85 importance values were generated by calculating the covariance of each feature and
86 PHC_{Global} . We generated brain maps showing the average feature importance across
87 100 out-of-sample model predictions. Maps were generated for the combined SVM and
88 for each unimodal SVM.

89

Name	Pathology	Variable type	Description
A β composite	A β	Continuous	A β SUVR in summary composite region
Centiloid	A β	Continuous	Linear transformation of A β composite SUVR ⁸
A β SUVR>1.11	A β	Binary	Cutoff from Landau et al. ⁹
A β SUVR>1.24	A β	Binary	Cutoff from Su et al. ¹⁰
A β SUVR>1.42	A β	Binary	Cutoff from Jack et al. ¹¹ (reliable worsening)
A β SUVR>1.30	A β	Binary	Cutoff from Jack et al. ¹¹ (specificity)
Centiloid>15	A β	Binary	Binary cutoff for Centiloid
Centiloid>20	A β	Binary	Binary cutoff for Centiloid
Centiloid>25	A β	Binary	Binary cutoff for Centiloid
Centiloid>30	A β	Binary	Binary cutoff for Centiloid
A β composite (GMM)	A β	Binary	A β composite SUVR binarized with a GMM
A β composite (z>2.0)	A β	Binary	Z-score cutoff of 2 for A β composite SUVR
A β composite (z>2.5)	A β	Binary	Z-score cutoff of 2.5 for A β composite SUVR
A β composite (Quartiles)	A β	Non-binary categorical	Quartiles of the A β composite SUVR
Centiloid (Quartiles)	A β	Non-binary categorical	Quartiles of Centiloid
Mattsson staging	A β	Non-binary categorical	A β –PET staging system ²
Collij staging	A β	Non-binary categorical	A β –PET staging system ¹
A β composite (BIZ)	A β	Non-binary categorical	Binarization with an intermediate zone for A β composite
Centiloid (BIZ)	A β	Non-binary categorical	Binarization with an intermediate zone for Centiloid
MT tau SUVR	Tau	Continuous	Tau SUVR in meta-temporal composite region
Braak I SUVR	Tau	Continuous	Tau SUVR in Braak I composite region
Braak III/IV SUVR	Tau	Continuous	Tau SUVR in Braak III/IV composite region
Braak V/VI SUVR	Tau	Continuous	Tau SUVR in Braak V/VI composite region
MT tau (GMM)	Tau	Binary	Meta-temporal tau SUVR binarized with a GMM
MT tau (z>2.0)	Tau	Binary	Z-score cutoff of 2 for MT tau SUVR
MT tau (z>2.5)	Tau	Binary	Z-score cutoff of 2.5 for MT tau SUVR
Tau SUVR>1.20	Tau	Binary	Cutoff from Jack et al. ¹¹ (sensitivity)
Tau SUVR>1.21	Tau	Binary	Cutoff from Jack et al. ¹¹ (specificity)
Tau SUVR>1.23	Tau	Binary	Cutoff from Jack et al. ¹¹ (accuracy-young)
Tau SUVR>1.33	Tau	Binary	Cutoff from Jack et al. ¹¹ (accuracy-matched)
MT tau (Quartiles)	Tau	Non-binary categorical	Quartiles of MT tau SUVR
MT tau (BIZ)	Tau	Non-binary categorical	Binarization with an intermediate zone for MT tau SUVR

Braak staging (3)	Tau	Non-binary categorical	Braak staging based on 3 stage model (I, III/IV, V/VI)
Braak staging (6)	Tau	Non-binary categorical	Braak staging based on 6 stage model (I, III, V, V, VI)
Hippocampus	Neurodegen.	Continuous	Hippocampal volume
MT volume	Neurodegen.	Continuous	Volume of the MT composite region
Hippocampus (z<-2.0)	Neurodegen.	Binary	Z-score cutoff of 2.0 for hippocampal volume
Hippocampus (z<-2.5)	Neurodegen.	Binary	Z-score cutoff of 2.5 for hippocampal volume
MT volume (z<-2.0)	Neurodegen.	Binary	Z-score cutoff of 2.0 for MT volume
MT volume (z<-2.5)	Neurodegen.	Binary	Z-score cutoff of 2.5 for MT volume
Hippocampus (Quartiles)	Neurodegen.	Non-binary categorical	Quartiles of hippocampal volume
MT volume (Quartiles)	Neurodegen.	Non-binary categorical	Quartiles of MT volume

eTable 1. Listing of all image-based AT(N) biomarkers used in cognitive prediction models.

91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107

Name	Citation	Regions
A β composite	^{12,13}	caudal middle frontal, lateral orbitofrontal, medial orbitofrontal, pars opercularis, pars orbitalis, pars triangularis, rostral middle frontal, superior frontal, frontal pole, caudal anterior cingulate, isthmus cingulate, posterior cingulate, rostral anterior cingulate, inferior parietal, precuneus, superior parietal, supramarginal, inferior temporal, middle temporal, superior temporal
MT	¹¹	entorhinal, amygdala, fusiform, inferior temporal, middle temporal
Braak I	^{14,15}	entorhinal
Braak III		parahippocampal, fusiform, lingual, amygdala
Braak IV		middle temporal, caudal anterior cingulate, rostral anterior cingulate, posterior cingulate, isthmus cingulate, insula, inferior temporal, temporal pole
Braak V		superior frontal, lateral orbitofrontal, medial orbitofrontal, frontal pole, caudal middle frontal, rostral middle frontal, pars opercularis, pars orbitalis, pars triangularis, lateral occipital, supramarginal, inferior parietal, superior temporal, superior parietal, precuneus, bank of the superior temporal sulcus, transverse temporal
Braak VI		pericalcarine, postcentral, cuneus, precentral, paracentral
Mattsson Early		¹
Mattsson Intermediate	bank SSTS, caudal middle frontal, cuneus, frontal pole, fusiform, inferior parietal, inferior temporal, lateral occipital, middle temporal, parahippocampal, pars opercularis, pars orbitalis, pars triangularis, putamen, rostral anterior cingulate, rostral middle frontal, supramarginal	
Mattsson Late	lingual, pericalcarine, paracentral, precentral, postcentral	
Collij 1	²	posterior cingulate, isthmus cingulate, anterior cingulate (caudal+rostral)
Collij 2		lateral orbitofrontal, paracentral, precuneus, medial orbitofrontal, inferior frontal (pars opercularis+pars orbitalis+pars triangularis)
Collij 3		insula, fusiform, precentral, inferior temporal, parahippocampal, collijinferiorfrontal, superior frontal, lingual, supramarginal, inferior parietal, cuneus, middle frontal (rostral+caudal)
Collij 4		lateral occipital, superior parietal, middle temporal, superior temporal, postcentral, entorhinal, frontal pole, temporal pole

108 **eTable 2.** List of Freesurfer regions used for composite regions. Citations are included
109 for papers which defined these composites. For Collij stging composites, regions
110 shown joined by plus signs are meta-ROIs constructed prior to averaging for the
111 composite, as described in the original paper². A β =amyloid-beta, MT=meta-temporal,
112 ROI=region of interest.

113

114

115

116

117

118

119

120

121

122

Model	A β	Tau	Neurodegen
Baseline	-	-	-
A _{BIN}	Binary	-	-
T _{BIN}	-	Binary	-
N _{BIN}	-	-	Binary
A _{CAT}	Non-binary categorical	-	-
T _{CAT}	-	Non-binary categorical	-
N _{CAT}	-	-	Non-binary categorical
A _{CON}	Continuous	-	-
T _{CON}	-	Continuous	-
N _{CON}	-	-	Continuous
A _{BIN} /T _{BIN} /N _{BIN}	Binary	Binary	Binary
A _{CAT} /T _{CAT} /N _{CAT}	Non-binary categorical	Non-binary categorical	Non-binary categorical
A _{CON} /T _{CON} /N _{CON}	Continuous	Continuous	Continuous
A _{CAT} /T _{BIN} /N _{BIN}	Non-binary categorical	Binary	Binary
A _{BIN} /T _{CAT} /N _{BIN}	Binary	Non-binary categorical	Binary
A _{BIN} /T _{BIN} /N _{CAT}	Binary	Binary	Non-binary categorical
A _{CON} /T _{BIN} /N _{BIN}	Continuous	Binary	Binary
A _{BIN} /T _{CON} /N _{BIN}	Binary	Continuous	Binary
A _{BIN} /T _{BIN} /N _{CON}	Binary	Binary	Continuous

123 **eTable 3.** List of linear models predicting PHC_{Global} from AT(N) biomarkers. Models
124 were trained with a nested-cross validation scheme where the inner loop was used to
125 select the best performing biomarkers, after grouping by pathology (A β , tau,
126 neurodegeneration) and variable type. BIN, CAT, and CON are used to represent
127 binary, non-binary categorical, and continuous variables (respectively). Dashes are
128 shown to indicate omission of the corresponding biomarker in the model. All models
129 also had age, sex, and *APOE* E4 status included as covariates.

130

131

132

133

134

135

136

137

138

139

140

	CDR=0.0	CDR=0.5	CDR=1.0+	p-value
n	223	130	30	
Age	73.76 (7.07)	75.73 (8.32)	77.78 (8.48)	0.005
Sex (M/F)	96/127	75/55	16/14	0.026
APOE E4+	79 (35.4%)	45 (34.6%)	13 (43.3%)	0.659
Centiloid	19.92 (35.65)	41.74 (54.70)	69.79 (48.77)	<0.001
PHC_{Global}	0.84 (0.36)	0.35 (0.46)	-0.47 (0.55)	<0.001

eTable 4: Characteristics for the subsample with longitudinal cognitive followup.


141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165

	CDR=0.0	CDR=0.5	CDR=1.0+	p-value
n	143	83	20	
Age	73.29 (7.50)	74.26 (8.31)	75.91 (9.34)	0.322
Sex (M/F)	59/94	54/29	10/10	0.003
APOE E4+	49 (34.3%)	29 (34.9%)	12 (60.0%)	0.076
Centiloid	19.94 (38.52)	45.26 (55.40)	74.68 (48.25)	<0.001
PHC_{Global}	0.87 (0.35)	0.32 (0.50)	-0.27 (0.53)	<0.001

166 **eTable 5:** Characteristics for the subsample with imaging and CSF biomarker
167 assessments.

168

169




171

172 **eFigure 1:** Comparison of partial volume corrected (PVC) and non-PVC tau predictors
 173 for modeling cognition. **A.** Boxplots of cross-validated accuracy (RMSE) for models
 174 including a single tau predictor and covariates. **B.** Boxplots of cross-validated accuracy
 175 (RMSE) for models with the best selected tau predictors. Solid colors indicate models
 176 without tau PVC, while hatches indicate models with tau PVC. In both panels, the
 177 baseline model (just covariates) is shown in gray, with the dotted line indicating its mean
 178 performance. Gold stars indicate a significant improvement in accuracy relative to the
 179 baseline model (*p<0.05, **p<0.01, ***p<0.001). No significant differences were found
 180 for comparisons of PVC and non-PVC models (all p>0.05).

181

182



183

184 **eFigure 2:** Regional weights for SVM models which included only A β (A, A_{SVM}), tau (B,
 185 T_{SVM}), or gray matter volume (C, N_{SVM}).

186

187

188

189

190


191

192

193

194

195



196

197 **eFigure 3:** Boxplots showing cross-validated accuracy (RMSE) measures for predicting
 198 PHC_{Global} in CU (A) and CI (B) individuals. Individual and combination biomarker
 199 models are compared against a baseline model using only covariates (mean
 200 performance indicated by dotted line) to predict PHC_{Global}. Colors are used to indicate
 201 the variable type of included biomarkers (yellow: binary, purple: non-binary categorical,
 202 red: continuous, blue: SVM). Lighter coloring indicates models which only have a single
 203 pathology assessment, while darker coloring indicates models which have A β , tau, and
 204 neurodegeneration biomarkers. Gold stars indicate a significant improvement in
 205 accuracy relative to the baseline model (*p<0.05, **p<0.01, ***p<0.001).

206

207


208

209

210

211

212



213

214 **eFigure 4:** Boxplots showing cross-validated accuracy (RMSE) measures for predicting
 215 PHC_{Global} in CU (A) and CI (B) individuals. Combination biomarker models with non-
 216 binary variable types are compared against a baseline model with binary biomarker
 217 definitions (mean performance indicated by dotted line). Colors are used to indicated
 218 the variable type of included biomarkers (yellow: binary, purple: non-binary categorical,
 219 red: continuous, blue: SVM). Lighter coloring indicates models which only have a single
 220 pathology assessment, while darker coloring indicates models which have A β , tau, and
 221 neurodegeneration biomarkers. Gold stars indicate a significant improvement in
 222 accuracy relative to the baseline model (*p<0.05, **p<0.01, ***p<0.001).

223

224


225

226

227

228

229



230

231 **eFigure 5:** Results from experiments predicting the longitudinal change in PHC_{Global} . **A.**
 232 Individual and combination biomarker models are compared against a baseline model
 233 using only covariates (mean performance indicated by dotted line). **B.** Combination
 234 biomarker models with non-binary variable types are compared against a baseline
 235 model with binary biomarker definitions (mean performance indicated by dotted line). In
 236 both panels, colors are used to indicate the variable type of included biomarkers
 237 (yellow: binary, purple: non-binary categorical, red: continuous, blue: SVM). Lighter
 238 coloring indicates models which only have a single pathology assessment, while darker
 239 coloring indicates models which have $A\beta$, tau, and neurodegeneration biomarkers.
 240 Gold stars indicate a significant improvement in accuracy relative to the topmost model.
 241 Gray stars and bars highlight significant pairwise differences between individual models.
 242 Statistical results are derived from Nadeau-Bengio t-tests with correction for multiple
 243 comparisons (* $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$).


244

245

246

247


248



249

250 **eFigure 6:** Boxplots showing cross-validated accuracy estimates (RMSE) for models
 251 predicting neuropsychological performance from biomarkers. Panels show experiments
 252 using memory (A), executive functioning (B), language (C), and visuospatial (D)
 253 composites from the PHC as dependent variables. Combination biomarker models with
 254 non-binary variable types are compared against a baseline model with binary biomarker
 255 definitions (mean performance indicated by dotted line). In all panels, colors are used
 256 to indicate the variable type of included ATN biomarkers (yellow: binary, purple: non-
 257 binary categorical, red: continuous, blue: SVM). Lighter coloring indicates models which
 258 only have a single pathology assessment, while darker coloring indicates models which
 259 have A β , tau, and neurodegeneration biomarkers. Gold stars indicate a significant
 260 improvement in accuracy relative to the topmost model.

261



262

263 **eFigure 7:** Alternate version of main text Figure 1 including CSF predictors alongside
 264 imaging-based ones.

265

266

267

268

269

270

- 272 1. Mattsson N, Palmqvist S, Stomrud E, Vogel J, Hansson O. Staging β -Amyloid
273 Pathology With Amyloid Positron Emission Tomography. *JAMA Neurology*.
274 2019;76(11):1319-1329. doi:10.1001/jamaneurol.2019.2214
- 275 2. Collij LE, Heeman F, Salvadó G, et al. Multitracer model for staging cortical amyloid
276 deposition using PET imaging. *Neurology*. 2020;95(11):e1538-e1553.
277 doi:10.1212/WNL.0000000000010256
- 278 3. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. *Acta*
279 *Neuropathol*. 1991;82(4):239-259. doi:10.1007/BF00308809
- 280 4. Braak H, Alafuzoff I, Arzberger T, Kretschmar H, Del Tredici K. Staging of
281 Alzheimer disease-associated neurofibrillary pathology using paraffin sections and
282 immunocytochemistry. *Acta Neuropathol*. 2006;112(4):389-404.
283 doi:10.1007/s00401-006-0127-z
- 284 5. Hsu CW, Chang CC, Lin CJ. A Practical Guide to Support Vector Classification.
285 Published online 2003. <https://www.csie.ntu.edu.tw/~cjlin/papers/guide/guide.pdf>
- 286 6. Haufe S, Meinecke F, Görgen K, et al. On the interpretation of weight vectors of
287 linear models in multivariate neuroimaging. *NeuroImage*. 2014;87:96-110.
288 doi:10.1016/j.neuroimage.2013.10.067
- 289 7. Chen J, Ooi LQR, Tan TWK, et al. Relationship between prediction accuracy and
290 feature importance reliability: An empirical and theoretical study. *Neuroimage*.
291 2023;274:120115. doi:10.1016/j.neuroimage.2023.120115
- 292 8. Klunk WE, Koeppe RA, Price JC, et al. The Centiloid Project: standardizing
293 quantitative amyloid plaque estimation by PET. *Alzheimers Dement*. 2015;11(1):1-
294 15.e1-4. doi:10.1016/j.jalz.2014.07.003
- 295 9. Landau SM, Mintun MA, Joshi AD, et al. Amyloid deposition, hypometabolism, and
296 longitudinal cognitive decline. *Annals of Neurology*. 2012;72(4):578-586.
297 doi:10.1002/ana.23650
- 298 10. Su Y, Flores S, Wang G, et al. Comparison of Pittsburgh compound B and
299 florbetapir in cross-sectional and longitudinal studies. *Alzheimers Dement (Amst)*.
300 2019;11:180-190. doi:10.1016/j.dadm.2018.12.008
- 301 11. Jack CR, Wiste HJ, Weigand SD, et al. Defining imaging biomarker cut-points for
302 brain aging and Alzheimer's disease. *Alzheimers Dement*. 2017;13(3):205-216.
303 doi:10.1016/j.jalz.2016.08.005

- 304 12. Mormino EC, Kluth JT, Madison CM, et al. Episodic memory loss is related to
305 hippocampal-mediated beta-amyloid deposition in elderly subjects. *Brain*.
306 2009;132(Pt 5):1310-1323. doi:10.1093/brain/awn320
- 307 13. Jagust WJ, Landau SM, Shaw LM, et al. Relationships between biomarkers in aging
308 and dementia. *Neurology*. 2009;73(15):1193-1199.
309 doi:10.1212/WNL.0b013e3181bc010c
- 310 14. Therriault J, Pascoal TA, Lussier FZ, et al. Biomarker modeling of Alzheimer's
311 disease using PET-based Braak staging. *Nat Aging*. 2022;2(6):526-535.
312 doi:10.1038/s43587-022-00204-0
- 313 15. Pascoal TA, Therriault J, Benedet AL, et al. 18F-MK-6240 PET for early and late
314 detection of neurofibrillary tangles. *Brain*. 2020;143(9):2818-2830.
315 doi:10.1093/brain/awaa180
- 316